BioForge, a precision manufacturing foundry based in Pittsburgh, PA, US, has completed a breakthrough project demonstrating a 50% reduction in the cost of producing microarray patches (MAPs).
The achievement marks a significant step forward for microneedle-based drug delivery by showing that MAPs can be manufactured at scale and at commercially viable price points — a hurdle that has long limited broader industry adoption.
MAPs — bandage-like patches covered with microscopic needles that deliver drugs or vaccines — have traditionally remained in the academic proof-of-concept phase.
Although the underlying science has been well established, the key challenge has been translating laboratory success into scalable, cost-effective manufacturing.
This latest collaboration shows that large-scale MAP production is not only technically achievable but can also meet the cost targets necessary to move the field toward commercial reality.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.